EUCTR2005-000206-31-IT进行中（未招募）不适用
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. - Phase III study of recombinant human C1 inhibitorPatients with acute attacks of hereditary angioedemaMedDRA version: 8Level: LLTClassification code 10019860EUCTR2005-000206-31-ESaboratorios Dr. Esteve, S.A.32
进行中（未招募）
1 期
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. - Phase III study of recombinant human C1 inhibitorPatients with acute attacks of hereditary angioedema.MedDRA version: 9.1 Level: LLT Classification code 10019860 Term: Hereditary angioedemaEUCTR2005-000206-31-GBPharming Technologies B.V.32
进行中（未招募）
不适用
A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedemaEUCTR2004-004282-15-ITPHARMING TECHNOLOGIES B.V.
已完成
不适用
A randomized, placebo-controlled, double-blind phase I study to explore safety, tolerability and pharmacodynamics of Cypep-1 in subjects with cutaneous wartsCutaneous wartswarts10014982NL-OMON48409Cytovation AS58
已完成
不适用
Evaluation of the safety, tolerability and pharmacokinetics of repeated oral doses of Priaculin in healthy male volunteersHealthy male volunteersISRCTN32485300Dr. Willmar Schwabe GmbH & Co. KG (Germany)32